Press Releases

Date Title
January 28, 2020
Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010
CRANBURY, N.J. , Jan. 28, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA -approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has
December 26, 2019
Outlook Therapeutics Announces Completion of Warrant Restructuring
CRANBURY, N.J. , Dec. 26, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA -approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has
December 23, 2019
Outlook Therapeutics Announces Warrant Amendment and Restructuring of Senior Secured Notes in Separate Transactions
CRANBURY, N.J. , Dec. 23, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA -approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has
December 19, 2019
Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2019
Topline results from the NORSE 1 study of ONS-5010 expected to be announced in the third quarter of calendar 2020 Enrollment in the NORSE 2 study underway SPA agreement reached with FDA for NORSE 4, 5 and 6 studies CRANBURY, N.J. , Dec. 19, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.
December 3, 2019
Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010
ONS-5010, an investigational ophthalmic formulation of bevacizumab for retinal indications, is currently in two clinical trials to treat wet age-related macular degeneration (wet AMD – NORSE 1 and 2).   SPAs for clinical trial protocols for NORSE 4 for branch retinal vein occlusion (“BRVO”) and
September 11, 2019
Outlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare Conference
CRANBURY, N.J. , Sept. 11, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it is scheduled to participate in the Ladenburg Thalmann 2019 Healthcare Conference being held at the Sofitel New York in New York on September 24 th .
August 27, 2019
Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference
CRANBURY, N.J. , Aug. 27, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it is scheduled to participate in the H.C. Wainwright 21st Annual Healthcare Conference that is being held at the Lotte New York Palace Hotel in New York on September 9
August 20, 2019
Outlook Therapeutics Completes Patient Enrollment for NORSE 1 a Phase 3 Clinical Trial for ONS-5010 in Wet AMD
Initial data expected to be announced in calendar Q3 2020 CRANBURY, N.J. , Aug. 20, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, an ophthalmic bevacizumab product candidate for the
August 14, 2019
Outlook Therapeutics Provides Business Update and Reports Financial Results for Third Quarter of Fiscal 2019
CRANBURY, N.J. , Aug. 14, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”) today reported business highlights and financial results for its third quarter ended June 30, 2019 . Recent Highlights: NORSE 2 (formerly “ONS-5010-002”) Phase 3 clinical trial begins dosing
July 16, 2019
Outlook Therapeutics Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD
Full enrollment expected to occur in calendar Q4 2019 CRANBURY, N.J. , July 16, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, a proprietary ophthalmic bevacizumab product candidate
Displaying 11 - 20 of 81